Key result
Multimodal therapy improves survival up to ~89% in young patients with ATRT.
Why the study?
Atypical teratoid rhabdoid tumors have a dismal prognosis when treated with conventional chemotherapy only, though recent multimodal strategies have improved survival.
Do multimodal strategies improve survival in young children with atypical teratoid rhabdoid tumors compared to conventional chemotherapy?
Do multimodal strategies improve survival in young children with atypical teratoid rhabdoid tumors compared to conventional chemotherapy?
Multimodal strategies combining high-dose chemotherapy, radiotherapy, and/or intrathecal chemotherapy improve survival in young children with ATRT, with survival rates ranging from 37.1% to 88.9%.
May support multimodal ATRT regimens in young children; leaves open superiority over conventional chemotherapy.
Atypical teratoid rhabdoid tumors are rare embryonal tumors of the nervous system mainly seen in very young children with aggressive behavior and dismal prognosis when treated with conventional chemotherapy only. More recent multimodal strategies combining, variably, high dose chemotherapy, radiotherapy and or intrathecal chemotherapy have led to some stride in survival. We present the results of the most recent clinical trials and registry data for patients treated with these multimodal approaches with survival ranging from 37.1% to 88.9%. We review the current consensus of the molecular characterization of these tumors into 3 subgroups (ATRT-TYR, ATRT-SHH and ATRT-MYC) and discuss the potential clinical impact of molecular subgrouping on survival. We explore other therapeutic tools including intrathecal chemotherapy and maintenance and possible new targeted agents for patients failing multimodal strategies.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) conducted a review in Atypical teratoid rhabdoid tumors (ATRT). Multimodal strategies (high dose chemotherapy, radiotherapy, intrathecal chemotherapy) was evaluated on Survival. Multimodal strategies combining high dose chemotherapy, radiotherapy, and/or intrathecal chemotherapy for young patients with ATRT have improved survival, with rates ranging from 37.1% to 88.9%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: